{
    "clinical_study": {
        "@rank": "114320", 
        "arm_group": [
            {
                "arm_group_label": "GLPG0634 capsule fasted", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of GLPG0634 as capsules in fasted condition"
            }, 
            {
                "arm_group_label": "GLPG0634 tablet fasted", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of GLPG0634 as tablets in fasted condition"
            }, 
            {
                "arm_group_label": "GLPG0634 tablet fed", 
                "arm_group_type": "Active Comparator", 
                "description": "Single dose of GLPG0634 as tablets in fed condition"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the amount of compound present in the blood\n      (relative bioavailability) after a single administration of GLPG0634 as a tablet versus a\n      capsule in fasted conditions in male healthy subjects.\n\n      Also, the effect of food on the bioavailability of the tablet formulation will be studied as\n      well as the safety and tolerability of single oral doses of GLPG0634 given either as capsule\n      or tablet."
        }, 
        "brief_title": "Oral Bioavailability of Two Solid Formulations of GLPG0634", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male, age 40-60 years\n\n          -  BMI between 18-30 kg/m2\n\n        Exclusion Criteria:\n\n          -  Any condition that might interfere with the procedures or tests in this study\n\n          -  Drug or alcohol abuse\n\n          -  Smoking"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01915667", 
            "org_study_id": "GLPG0634-CL-107"
        }, 
        "intervention": [
            {
                "arm_group_label": "GLPG0634 capsule fasted", 
                "description": "single oral dose of 200 mg GLPG0634 given as capsules in fasted condition", 
                "intervention_name": "200 mg GLPG0634 as capsules, fasted", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "GLPG0634 tablet fasted", 
                "description": "single oral dose of 200 mg GLPG0634 given as tablets in fasted condition", 
                "intervention_name": "200 mg GLPG0634 as tablets, fasted", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "GLPG0634 tablet fed", 
                "description": "single oral dose of 200 mg GLPG0634 given as tablets in fed condition", 
                "intervention_name": "200 mg GLPG0634 as tablets, fed", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 16, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Antwerp", 
                    "country": "Belgium"
                }, 
                "name": "SGS LSS Clinical Pharmacology Unit Antwerp"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "3", 
        "official_title": "Bioavailability Study Comparing Two Solid Oral Formulations of GLPG0634 in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Galapagos NV", 
            "last_name": "Pille Harrison, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To characterize and compare the amount of GLPG0634 and metabolite in plasma (relative bioavailability) in male healthy subjects after a single administration of either a capsule or tablet formulation in a fasted condition. For the tablet formulation, also the amount of GLPG0634 and metabolite in plasma will be evaluated after fasting and in fed condition.", 
            "measure": "The amount of GLPG0634 and metabolite in plasma after a single dose of GLPG0634 as capsules or tablets", 
            "safety_issue": "No", 
            "time_frame": "From predose (before first study drug administration) up to 144 hours post last study drug administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01915667"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To evaluate the safety and tolerability of GLPG0634 after a single oral dose as capsules or tablets, either fasted or fed, in male healthy subjects in terms of adverse events (AEs), abnormalities in laboratory tests, physical examinations, vital signs and electrocardiogram (ECG)", 
            "measure": "The number of subjects with adverse events, abnormal lab tests, physical examinations, vital signs and ECG after a single dose of GLPG0634 as capsules or tablets", 
            "safety_issue": "Yes", 
            "time_frame": "Between screening and 7-10 days after the last dose"
        }, 
        "source": "Galapagos NV", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Galapagos NV", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}